Panbela Therapeutics (Panbela Therapeutics) EBIT : $-27.31 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Panbela Therapeutics EBIT?

Panbela Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-7.20 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-27.31 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Panbela Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 was -263.93%. Panbela Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Panbela Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -464.85%.

Panbela Therapeutics EBIT Historical Data

The historical data trend for Panbela Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panbela Therapeutics EBIT Chart

Panbela Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-4.42

-5.05

-10.61

-34.76

-25.13

Panbela Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-5.01	-5.91	-7.78	-6.42	-7.20

Competitive Comparison of Panbela Therapeutics's EBIT

For the Biotechnology subindustry, Panbela Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Panbela Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panbela Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Panbela Therapeutics's EV-to-EBIT falls into.

Panbela Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.31 Mil.

Panbela Therapeutics (OTCPK:PBLA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Panbela Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-26.904 * ( 1 - 1.9% )	/	( (10.258	+	9.742)	/ 2 )
=	-26.392824	/	10
=	-263.93 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11.802	-	10.802	-	( 2.578	-	max(0, 12.318	-	3.06	+	2.578	))
=	10.258

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.527	-	9.519	-	( 0.262	-	max(0, 10.519	-	1.785	+	0.262	))
=	9.742

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Panbela Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-28.78	/	( ( (0 + max(-11.019, 0))	+	(0 + max(-8.309, 0)) )	/	2 )
=	-28.78	/	( ( 0	+	0 )	/	2 )
=	-28.78	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.299)	-	(10.802	+	0	+	0.516)
=	-11.019

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.21)	-	(9.519	+	0	+	0)
=	-8.309

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Panbela Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-27.305	/	5.874
	=	-464.85 %

Panbela Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Panbela Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Panbela Therapeutics (Panbela Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panbela Therapeutics Inc (OTCPK:PBLA) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387

Website

https://www.panbela.com

Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.

Executives

Jennifer K. Simpson	director, officer: President and CEO	C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Susan Horvath	officer: V.P. of Finance & CFO	4645 ITHACA LANE, PLYMOUTH MN 55446
Jeffrey E. Jacob	director	712 VISTA BLVD #305, WACONIA MN 55387
Daniel Donovan	director	712 VISTA BLVD #305, WACONIA MN 55387
Paul W. Schaffer	director	712 VISTA BLVD #305, WACONIA MN 55387
Arthur Fratamico	director	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Ryan R. Gilbertson 2012 Irrevocable Trust	10 percent owner	1000 PARKER'S LAKE RD, WAYZATA MN 55391
Ryan Randall Gilbertson	10 percent owner	130 LAKE ST. WEST, WAYZATA MN 55391
Donald Robert Schemel	director	712 VISTA BLVD #305, WACONIA MN 55387
Dalvir S Gill	director	712 VISTA BLVD SUITE 305, WACONIA MN 55387
Scott Kellen	officer: Chief Financial Officer	3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Jeffrey S Mathiesen	director	43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167
Paulson J Robert Jr	director
Daniel E. Ryweck	officer: Chief Financial Officer	712 VISTA BLVD #305, WACONIA MN 55387
Michael T. Cullen	director	712 VISTA BLVD, #305, WACONIA MN 55387